Literature DB >> 29263058

Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update.

Yanhua Gao1, Michael Barras1,2, Stefanie Hennig3.   

Abstract

Entities:  

Keywords:  Bayesian forecasting; cystic fibrosis; tobramycin

Mesh：

Substances：

Year:  2018        PMID： 29263058      PMCID： PMC5826124          DOI： 10.1128/AAC.01972-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

3.  TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine.

Authors:  Sebastian G Wicha; Martin G Kees; Alexander Solms; Iris K Minichmayr; Alexander Kratzer; Charlotte Kloft
Journal:  Int J Antimicrob Agents       Date:  2015-01-10       Impact factor: 5.283

4.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.

Authors:  Stefanie Hennig; Franziska Holthouse; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

6.  Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents.

Authors:  B Charpiat; V Breant; C Pivot-Dumarest; P Maire; R Jelliffe
Journal:  Ther Drug Monit       Date:  1994-04       Impact factor: 3.681

7.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

8.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 9.  Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.

Authors:  R W Jelliffe; A Schumitzky; M Van Guilder; M Liu; L Hu; P Maire; P Gomis; X Barbaut; B Tahani
Journal:  Ther Drug Monit       Date:  1993-10       Impact factor: 3.681

Review 10.  Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Authors:  A S Darwich; K Ogungbenro; A A Vinks; J R Powell; J-L Reny; N Marsousi; Y Daali; D Fairman; J Cook; L J Lesko; J S McCune; Caj Knibbe; S N de Wildt; J S Leeder; M Neely; A F Zuppa; P Vicini; L Aarons; T N Johnson; J Boiani; A Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875
  10 in total
  2 in total

1.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

2.  Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities.

Authors:  Ron J Keizer; Rob Ter Heine; Adam Frymoyer; Lawrence J Lesko; Ranvir Mangat; Srijib Goswami
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.